Skip to main content Skip to main navigation menu Skip to site footer

Mortality comparison between axillary lymph node dissection (ALND) and sentinel lymph node biopsy (SND) among breast cancer pantient: A meta-analysis and systematic review study

Abstract

Introduction: Axillary lymph node dissection (ALND) is a crucial surgical procedure for breast cancer. It has guaranteed locoregional control of the disease, guided adjuvant therapy, and functioned as a staging tool. However, over the past 25 years, a more conservative approach has become the standard for surgical management of the axilla. Because sentinel lymph node biopsy (SNB) is less invasive and less morbid than axillary lymph node dissection (ALND), it has become the standard surgical procedure for axillary staging of clinically node-negative breast cancer. This study aimed to compare the mortality of breast cancer patients receiving ALND and SNB procedure.

Methods: Our review includes randomized controlled trials of breast cancer patients undergoing ALND or SNB surgical techniques. A systematic literature search was performed from PubMed on December 2023 to search for articles reporting on survival rates between ALND vs SNB among breast cancer patients. The data obtained then underwent statistical evaluation, and a meta-analysis was conducted using Review Manager 5.4. In order to represent primary outcomes, the risk ratio was estimated using an inverse variance technique with a random-effects model. Heterogeneity was presented with total values, 95% confidence intervals (CI), and I values.

Results: As many as 208 articles were found in the PubMed database search, and only six studies were included in this study. The six included trials all used chemotherapy and radiotherapy for systematic treatment. The length of follow-up varied from 33 months to 15 years. The total number of patients in the trials was 3,585, and the study period was from 2011 to 2023. The pooled analysis of the mortality outcomes showed that the heterogeneity of the data was low (I2 21%, p = 0.4). In the pooled analysis, the mortality of patients with SNB for surgical treatment was not significantly different compared to patients with ALND (OR:0.88; 95% CI:0.65-1.19).

Conclusion: The mortality of patients undergoing SNB and ALND does not differ significantly, according to this pooled study. It demonstrates that the group without axillary dissection had a primary survival outcome that was not inferior to that of the dissection group.

References

  1. From the Divisions of Senology. N Engl J Med. 2003;7:546–53. Available from: www.nejm.org
  2. Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized Multicenter Trial of Sentinel Node Biopsy Versus Standard Axillary Treatment in Operable Breast Cancer: The ALMANAC Trial. JNCI: Journal of the National Cancer Institute. 2006;98(9):599–609. Available from: https://dx.doi.org/10.1093/jnci/djj158
  3. Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group trial Z0011. Journal of Clinical Oncology. 2007;25(24):3657–63. Available from: https://ascopubs.org/doi/10.1200/JCO.2006.07.4062
  4. Canavese G, Bruzzi P, Catturich A, Tomei D, Carli F, Garrone E, et al. Sentinel Lymph Node Biopsy Versus Axillary Dissection in Node-Negative Early-Stage Breast Cancer: 15-Year Follow-Up Update of a Randomized Clinical Trial. Ann Surg Oncol. 2016;23(8):2494–500. Available from: https://link.springer.com/article/10.1245/s10434-016-5177-4
  5. Giuliano AE, Hunt KK, Ballman K V., Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA. 2011;305(6):569–75.
  6. Canavese G, Bruzzi P, Catturich A, Tomei D, Carli F, Garrone E, et al. Sentinel Lymph Node Biopsy Versus Axillary Dissection in Node-Negative Early-Stage Breast Cancer: 15-Year Follow-Up Update of a Randomized Clinical Trial. Ann Surg Oncol. 2016;23(8):2494–500.
  7. Sávolt, Péley G, Polgár C, Udvarhelyi N, Rubovszky G, Kovács E, et al. Eight-year follow up result of the OTOASOR trial: The Optimal Treatment Of the Axilla – Surgery Or Radiotherapy after positive sentinel lymph node biopsy in early-stage breast cancer: A randomized, single centre, phase III, non-inferiority trial. European Journal of Surgical Oncology. 2017;43(4):672–9.
  8. Galimberti V, Cole BF, Viale G, Veronesi P, Vicini E, Intra M, et al. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. Lancet Oncol. 2018;19(10):1385–93.
  9. Tinterri C, Gentile D, Gatzemeier W, Sagona A, Barbieri E, Testori A, et al. Preservation of Axillary Lymph Nodes Compared with Complete Dissection in T1–2 Breast Cancer Patients Presenting One or Two Metastatic Sentinel Lymph Nodes: The SINODAR-ONE Multicenter Randomized Clinical Trial. Ann Surg Oncol. 2022;29(9):5732–44.
  10. Tinterri C, Canavese G, Gatzemeier W, Barbieri E, Bottini A, Sagona A, et al. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment. British Journal of Surgery. 2023;110(9):1143–52.
  11. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30. Available from: https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21387
  12. Moore MP, Kinne DW. Axillary Lymphadenectomy: A Diagnostic and Therapeutic Procedure. Vol. 66, Journal of Surgical Oncology. 1996.
  13. Nagel PHAF, Bruggink EDM, Wobbes T, Strobbe LJA. Arm Morbidity after Complete Axillary Lymph Node Dissection for Breast Cancer. Acta Chir Belg. 2003;103(2):212–6. Available from: https://www.tandfonline.com/doi/abs/10.1080/00015458.2003.11679409
  14. Budd DC, Cochran RC, Sturtz DL, Fouty WJ. Surgical morbidity after mastectomy operations. The American Journal of Surgery. 1978;135(2):218–20. Available from: http://www.americanjournalofsurgery.com/article/0002961078901034/fulltext
  15. Cc S, Donegan W. A biostatistical evaluation of complications from mastectomy. Surg Gynecol Obstet. 1974;
  16. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. NCCN Guidelines Insights: Breast Cancer, Version 1.2017. Journal of the National Comprehensive Cancer Network. 2017;15(4):433–51. Available from: https://jnccn.org/view/journals/jnccn/15/4/article-p433.xml
  17. Rónká R, Smitten K V., Sintonen H, Kotomáki T, Krogerus L, Leppänen E, et al. The impact of sentinel node biopsy and axillary staging strategy on hospital costs. Annals of Oncology. 2004;15(1):88–94.
  18. Singh Ranger G, Mokbel K. The evolving role of sentinel lymph node biopsy for breast cancer. European Journal of Surgical Oncology. 2003;29(5):423–5. Available from: http://www.ejso.com/article/S0748798303000386/fulltext
  19. Schrenk P, Shamiyeh A, Wayand W. Sentinel lymph-node biopsy compared to axillary lymph-node dissection for axillary staging in breast cancer patients. European Journal of Surgical Oncology. 2001;27(4):378–82. Available from: http://www.ejso.com/article/S0748798301911394/fulltext
  20. Poodt. De-escalating management of primary and locally recurrent breast cancer [Internet]. maastricht university; 2019. Available from: https://cris.maastrichtuniversity.nl/portal/en/publications/deescalating-management-of-primary-and-locally-recurrent-breast-cancer(19d79740-f072-469a-9960-7b8beba15c3e).html
  21. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: Highlights of the st gallen international expert consensus on the primary therapy of early breast Cancer 2013. Annals of Oncology. 2013;24(9):2206–23.

How to Cite

Herida, A. R., Dewi, S. P., & Herida, A. F. (2024). Mortality comparison between axillary lymph node dissection (ALND) and sentinel lymph node biopsy (SND) among breast cancer pantient: A meta-analysis and systematic review study. Bali Medical Journal, 13(1), 895–899. https://doi.org/10.15562/bmj.v13i1.5265

HTML
4

Total
5

Share

Search Panel

Alifia Ramadhani Herida
Google Scholar
Pubmed
BMJ Journal


Sari Puspita Dewi
Google Scholar
Pubmed
BMJ Journal


Akmal Fauzan Herida
Google Scholar
Pubmed
BMJ Journal